In this episode of Medsider Radio, we sat down with Dr. Meesha Dogan, co-founder and CEO of Cardio Diagnostics.

Meesha is a well-respected leader in the epigenetic space. After completing her Ph.D. in biomedical engineering, she co-founded Cardio Diagnostics and co-invented its patent-pending cardiac technologies, which seek to improve the early detection, diagnosis, and prevention of heart disease through objective risk assessment testing. 

In this interview, Meesha shares how her company was founded on the grounds of compelling scientific research. She also talks about the different methods to improve the clinical adoption of a device and explains the possible benefits of going public. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Meesha if you'd rather read the summary instead.